Evidence map›Paper›PMID 28332132›Full record

ReviewHeart failure reviews2017

Redefining the role of biomarkers in heart failure trials: expert consensus document.

Frank Kramer, Hani N Sabbah, James J Januzzi, Faiez Zannad, J Peter van Tintelen, Erik B Schelbert, Raymond J Kim, Hendrik Milting, Richardus Vonk, Brien Neudeck and 6 more

Abstract readReviewConsensus Statement
PubMed Publisher
In one paragraph

Review in Heart failure reviews, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Digital Tools-Regulatory Considerations for Application in Clinical Trials.Therapeutic innovation & regulatory science · 2023
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Frank KramerBAYER AG, Experimental Medicine Cardiovascular/Hematology, Aprather Weg 18a, 42133, Wuppertal, Germany. frank.kramer@bayer.com.ORCID 0000-0001-7701-912X
Hani N SabbahDivision of Cardiovascular Medicine, Department of Medicine, Henry Ford Hospital, 2799 West Grand Boulevard, Detroit, MI, 48202, USA.
James J JanuzziCardiology Division, Massachusetts General Hospital; Clinical Trial Design, Baim Institute for Clinical Research, Boston, MA, USA.
Faiez ZannadInserm Clinical Investigation Center 1403, Université de Lorraine, CHU de Nancy, Institut Lorrain du Coeur et des Vaisseaux CHU and University de Lorraine, Nancy, France.
J Peter van TintelenDepartment of Clinical Genetics, University of Amsterdam, Academic Medical Center, Amsterdam, The Netherlands.
Erik B SchelbertUPMC Cardiovascular Magnetic Resonance Center, University of Pittsburgh, Pittsburgh, PA, USA.
Raymond J KimDivision of Cardiology, Department of Medicine, Duke University Medical Center, Durham, NC, USA.
Hendrik MiltingHeart and Diabetes Center NRW, University Clinics of the Ruhr University, Erich and Hanna Klessmann-Institute for Cardiovascular Research and Development, Bad Oeynhausen, Germany.
Richardus VonkBAYER, Research & Clinical Sciences Statistics, Berlin, Germany.
Brien NeudeckMedtronic Diagnostics, 8200 Coral Sea Street, MVC43, Minneapolis, MN, 55112, USA.
Richard ClarkMedtronic Diagnostics, 8200 Coral Sea Street, MVC43, Minneapolis, MN, 55112, USA.
Klaus WitteLeeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK.
Wilfried DinhBAYER AG, Experimental Medicine Cardiovascular/Hematology, Aprather Weg 18a, 42133, Wuppertal, Germany.
Burkert PieskeDepartment of Internal Medicine and Cardiology, Charité University Medicine Berlin-Campus Virchow Klinikum, Augustenburger Platz 1, 13353, Berlin, Germany.
Javed ButlerDivision of Cardiology, Health Sciences Center, SUNY, T-16 Room 080, Stony Brook, NY, 11794, USA.
Mihai GheorghiadeCenter for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, 201 East Huron, Galter 3-150, Chicago, IL, 60611, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heart failure is a growing cardiovascular disease with significant epidemiological, clinical, and societal implications and represents a high unmet need. Strong efforts are currently underway by academic and industrial researchers to develop novel treatments for heart failure. Biomarkers play an important role in patient selection and monitoring in drug trials and in clinical management. The present review gives an overview of the role of available molecular, imaging, and device-derived digital biomarkers in heart failure drug development and highlights capabilities and limitations of biomarker use in this context.

Indexed as

ConsensusDisease ManagementHeart FailureBiomarkersClinical Trials as TopicDiagnostic ImagingHumansPatient SelectionBiomarkersBiomarkerClinical trialDrug developmentHeart failureImagingMedical device

Identifiers

PMID28332132

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.